WE PUBLISH LIMITED NUMBER OF

HIGH IMPACT & DECISION MAKING

RESEARCH & MARKET INTELLIGENCE REPORTS

YEARS in

PUBLISHING

INTELLIGENCE

REPORTS

SATISFIED

CUSTOMERS

WE TRACK NEARLY 4500 ACTIVE DRUG DEVELOPERS WORLDWIDE

AND PUBLISH EXCLUSIVE REPORTS​ ON

ONCOLOGY & NEUROLOGY DRUG DEVELOPMENT

Drug Development is complex process and requires different set of intelligence as per individual's need. We design two set of Reports - Comprehensive Series and Startups Series, both with slightly different objectives and are released at regular interval of time with updates.

METHEDOLOGY To present with a comprehensive story we closely monitor all year round activities and follows events, press releases, social media etc., for routine updates. Also, we subscribes to a large number of extensive & authentic resources to feed our internal Knowledgebase, which together with our primary research & personal interviews enables us to develop a quality and accurate intelligence, in form of Comprehensive Reports.

Drug Reports

COMPREHENSIVE INTELLIGENCE SERIES

Comprehensive Reports are designed to give complete Drug Discovery & Development  outlook in Neurology and Oncology along-with individual indication Pipeline Analysis and targets in development intelligence.

Reports provides individual clinical developmental profiles for all major drug indications. Each profile contains epidemiology, market forecast, current top selling therapies, PhIII pipeline drugs with their clinical trial design & combination drugs, key partners with expected launch.

OmicsX Reports covers worldwide active companies with largest number of active molecules in development.

Startup's Reports

IDENTIFY PARTNERS SERIES

Drug Developer’s Startup Series are specially designed to identify early stage researchers, having new ideas capable of changing the face of drug discovery. It covers entrepreneurs established in last few years with size less than $500 Mn USD.

Individual’s Technology, Management, Funding and Partnering capabilities are the  major highlights of the reports.

Startups Reports covers largest set of authentic drug developers worldwide with early stage molecules available for partnering and thus is the perfect tool to identify new partnering leads.

LARGEST COVERAGE

GUARANTEED

Each Individual Report creates immense authentic knowledge base (all information with references) on hundreds of proprietary technologies, M&A deals and partnering occurring among startups.

COMMON features

  • Worldwide coverage with largest number of active companies under analysis.
  • All Individual Companies Profiles, covered in single Report, to cross-check the intelligence generated in the report, with numerous links to justify all information.
  • LinkedIn & E-mail IDs of all Key Decision Maker(s), to identify and link with focused executives for partenering & business development opportunities.

Download previous year report

01

Oncology Reports

Data Intelligence Derived from

  • 2200+ Active Cancer Drug Developers.
  • 800+ Oncology Research supporting CROs
  • 600+ Venture Investors
  • 450+ Oncology Focused Events

 

RELEASED REPORTS

Ideas We Stand for:

Global Top 400 Immuno Oncology Startups 2020
Provides Complete Landscape on Latest Immuno-Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status among Startups.

Price – $ 3200 USD (Save $1000 USD use “FIRST1000” at checkout).

Released – October 2019

Check Inside Report

Also Check – Immuno Oncology Drug Developer CRM

Global Top 500 Oncology Startups 2017
Top 500 Oncology Startups Drug Developers established between 2010-2016.
First Innovative Report Helping You to Early Identify Startups & Partner with Them.

Price – $ 2800 USD (Save $1000 USD use “FIRST1000” at checkout).

Released – September 2016

Check Inside Report

Also Check – Oncology Startups CRM

Oncology Intelligence 2017 – Comprehensive Intelligence Report for Decision Making
Comprehensive Decision Making Intelligence derived from Active 1047 Oncology Drug Developers.
OI 2017 is a key update over previous report OI 2014, as it may covers 220 more oncology drug developers than the previous report. It also abandoned 103 companies, which were earlier covered in OI 2014, which were either acquired/merged or closed during the period.

Price – $ 3400 USD (Save $1000 USD use “FIRST1000” at checkout).

Released – January 2017

Check Inside Report

Also Check – Oncology Startups CRM

Oncology Intelligence 2014 – Comprehensive Intelligence Report for Decision Making
Comprehensive Decision Making Intelligence derived from Active 931 Oncology Drug Developers.
OI 2017 is a key update over previous report OI 2013, as it may covers 3398 more oncology drug developers than the previous report. It also abandoned 91 companies, which were earlier covered in OI 2013, which were either acquired/merged or closed during the period.

Price – NOT FOR SALE / AVAILABLE ON REQUEST

Released – January 2014

Check Inside Report

Oncology Intelligence 2013 – Comprehensive Intelligence Report for Decision Making
Oncology Intelligence 2013, was the first report in the series derived from Active 624 Oncology Drug Developers.

Price – NOT FOR SALE / AVAILABLE ON REQUEST

Released – January 2013

Check Inside Report

Oncology Drug Funding 2013
Report for the first time covers ‘ONCOLOGY FOCUSED’ 321 Active Venture Capital Firm Profiles their oncology investment portfolio | Criteria | Geographic focus etc.
Price – Freely Available for Download
Released – March 2013 Check Inside Report Also Check – Venture Investors in Drug Development – CRM

Oncology Intelligence Report 2017

Comprehensive Intelligence Series

Oncology Intelligence Report 2017, is designed to curtail down the efforts in identifying the real picture of present cancer drug development market, by bringing more authentic data under review and eliminating the undesired information.

Report for the first time identifies and profiles 1052 Active Cancer Drug Development companies from 33 countries worldwide, developing 2500+ cancer-targeting drugs.

Read More

ONCOLOGY STARTUPS 2017

Identify Partners Series

We bring you reliable car servicing and the security of knowing the mechanic working on your vehicle is fully trained and qualified.

Every mechanic in our workshop is passes advanced training participates in the Auto-Tech program. Auto-Tech training clinics are held nationwide and conducted by industry experts.

Read More

Immuno Oncology Startups 2020

Identify Partners Series

Report for the first time identifies and profiles Top 400 Active Immuno-Oncology Startup companies from 24 different countries worldwide, developing 581 cancer targeting drugs.

This highly precise 334 pages report is designed to keep information intact, informative and self-explanatory. Thus, Immuno-Oncology Startups 2020, will help organizations working on cancer research, to supercharge with lots of new decision-making information and jumpstart current partnering/marketing efforts..

Read More

RECENT OFFERINGS :

Starting 2019, all our intelligence reports comes with supporting CRM with complete contact details including social contacts, thus helping buyers to identify new partner companies based on report’s intelligence and connect in minutes using pre-filled Social CRM.

02

Neurology Reports

Data Intelligence Derived from

  • 1000+ Active Neurology Drug Developers
  • 500+ Neurology Research supporting CROs
  • 400+ Venture Investors
  • 150+ neurology Focused Events

 

RELEASED REPORTS

Ideas We Stand for:

Global Top 370 Neurology Startups 2020
Highly Innovative and Precise Report designed to Identify and Capture the Outlook of Top 370 Early Stage Neurology Drug Developers present in 26 countries worldwide.

Price – $ 3400 USD (Save $1000 USD use “FIRST1000” at checkout

Released – October 2020

Check Inside Report

Also Check – Neurology Startups CRM

Global Top 250 Neurology Startups 2017

Highly Innovative and Precise Report designed to Identify and Capture the Outlook of Top 250 Early Stage Neurology Drug Developers present in 24 countries worldwide.

Price – $ 2400 USD (Save $1000 USD use “FIRST1000” at checkout)
Released – November 2016
Check Inside Report

Releasing Soon – Jan 2020

Neurology Drug Report 2014
First time identifies and profiles 480 Active Neurology focused Drug Development companies. Creates immense authentic knowledge-base on hundreds of proprietary technologies, M&A deals and partnering occurring in domain in last 10 years.
Price – $ 2900 USD (Save $1000 USD use “FIRST1000” at checkout). Released – May 2014 Check Inside Report Also Check – Neurology Drug Developer CRM
Neurology Venture Funding 2013
Report for the first time covers ‘NEUROLOGY FOCUSED’ 210 Active Venture Capital Firm Profiles and their Neurology drug Development investment portfolio | Criteria | Geographic focus etc.
Released – April 2013 Check Inside Report Also Check – Venture Investors in Drug Development – CRM

Neurology Drug Report 2014

Comprehensive Intelligence Series

First time identifies and profiles 480 Active Neurology focused Drug Development companies.

Creates immense authentic knowledge-base on hundreds of proprietary technologies, M&A deals and partnering occurring in domain in last 10 years.

Read More

Neurology STARTUPS 2017

Identify Partners Series

Neurology Startups 2017 (First Edition), is highly innovative and precise report designed to identify and capture the outlook of early stage neurology drug developers companies present in 24 countries worldwide.

The report provides complete landscape on Top 250 Neurology Drug Developing startups established during 2010-2016.

Read More

Neurology Startups 2020

Identify Partners Series

Report for the first time identifies and profiles Top 370 Active Neurology Startups from 29 different countries worldwide, developing 448 molecules targeting Neurological disorders; established between 2010 – 2019; available for bio-partnering.

Single source largest collection of early stage Neurology pipeline; which otherwise is very difficult to identify and map for emerging companies. Report will help you in identifying the present and near-term future of Neurology Drug Discovery and development; thus making it a strong buy.

THIS REPORT IS REVISED & UPDATED EDITION OF NEUROLOGY STARTUPS 2017.

Read More

LIMITED TIME OFFER

FLAT $1,000 OFF FOR FIRST TIME REPORT BUYERS

We value our clients and are providing first time buyers this special discount, applicable on all Intelligence Reports including latest titles.

"self explanatory intelligence provided my team to quickly identify our needs and help us to reshape our marketing efforts..."
Jassica Doe
Director - Business Development

Trusted by

Over 150+ Companies